Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13D
Under the Securities Exchange Act of 1934
 
(Amendment No. 10)
 
Genomic Health, Inc
(Name of Issuer)

Common Stock, par value $0.0001 per share
 (Title of Class of Securities)

37244C101
 (CUSIP Number)

Leo Kirby
667 Madison Avenue, 21st Floor
New York, NY  10065
(212) 339-5633
 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 9, 2011
 (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.   ¨
 
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
Page 1 of 8 Pages
 
 
SCHEDULE 13D
 
CUSIP No.   37244C101      
  
Page   2   of   8   Pages

1
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Julian C. Baker
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) ¨
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
  ¨
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
41,250
8
SHARED VOTING POWER
8,037,234
9
SOLE DISPOSITIVE POWER
41,250
10
SHARED DISPOSITIVE POWER
8,037,234
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,078,484
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
      ¨
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
27.6%
14
TYPE OF REPORTING PERSON (See Instructions)
IN

 
Page 2 of 8 Pages
 

SCHEDULE 13D
 
CUSIP No.  37244C101      
  
Page   3   of   8    Pages

1
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Felix J. Baker
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) ¨
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
8,037,234
9
SOLE DISPOSITIVE POWER
  0
10
SHARED DISPOSITIVE POWER
8,037,234
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,037,234
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 ¨
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
27.4%
14
TYPE OF REPORTING PERSON (See Instructions)
IN
 
 
Page 3 of 8 Pages
 

This Amendment No. 10 to Schedule 13D is being filed by Julian C. Baker and Felix J. Baker (the “Reporting Persons”) to supplement the statements on Schedule 13D previously filed by them, as heretofore amended.  Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.
 
Item 5.
Interest in Securities of the Issuer.
 
Set forth below is the aggregate number of shares of Common Stock held, including shares that maybe acquired upon exercise of Options as of the date hereof by each of the following, together with the percentage of outstanding shares of Common Stock that such number represents based upon 29,265,991 shares outstanding, as reported on the company’s SEC Form 10Q filed on May 10, 2011. Such percentage figures are calculated on the basis that the Options owned by the Reporting Persons are deemed exercised for shares of Common Stock but other outstanding Options are not deemed exercised.
 
Name
  
Number of
Shares
    
Percent of Class
Outstanding
  
Baker Bros. Investments, L.P.
     173,897       0.6 %
Baker Bros. Investments II, L.P.
     20,518       0.1 %
667, L.P.
     1,253,653       4.3 %
Baker Brothers Life Sciences, L.P.
     6,059,449       20.7 %
14159, L.P.
     161,659       0.6 %
FBB Associates
     173,897       0.6 %
Baker/Tisch Investments, L.P.
     194,161       0.6 %
Julian C. Baker
     41,250       0.1 %
Total
     8,078,484       27.6 %
 
By virtue of their ownership of entities that have the power to control the investment decisions of the limited partnerships listed in the table above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power to vote or direct the vote of and shared power to dispose or direct the disposition of such securities.  Julian C. Baker and Felix J. Baker are also the sole partners of FBB Associates, a general partnership, and as such may be deemed to be beneficial owners of shares owned by FBB Associates and may be deemed to have shared power to vote or direct the vote and dispose or direct the disposition of those shares.
 
Julian C. Baker is a Director of the Company.
 
The following transactions in Common Stock were effected by the entities noted below during the sixty days preceding the filing of this statement. None of the reporting Persons has effected any other transactions in Common Stock during this period.

 
Page 4 of 8 Pages
 
 
Name
  
Date
  
Number of
Shares
  
Transaction
  
Price/ Share
  
Baker Bros. Investments II, L.P.
  
5/27/2011
     34  
Purchase
     27.0359  
Baker Brothers Life Sciences, L.P.
  
5/27/2011
     55183  
Purchase
     27.0359  
14159, L.P.
  
5/27/2011
     1464  
Purchase
     27.0359  
Baker Bros. Investments II, L.P.
  
5/31/2011
     12  
Purchase
     27.4607  
Baker Brothers Life Sciences, L.P.
  
5/31/2011
     18983  
Purchase
     27.4607  
14159, L.P.
  
5/31/2011
     504  
Purchase
     27.4607  
Baker Bros. Investments II, L.P.
  
5/31/2011
     22  
Purchase
     27.4836  
Baker Brothers Life Sciences, L.P.
  
5/31/2011
     36056  
Purchase
     27.4836  
14159, L.P.
  
5/31/2011
     957  
Purchase
     27.4836  
Baker Bros. Investments II, L.P.
  
6/1/2011
     23  
Purchase
     27.4668  
Baker Brothers Life Sciences, L.P.
  
6/1/2011
     37092  
Purchase
     27.4668  
14159, L.P.
  
6/1/2011
     885  
Purchase
     27.4668  
Baker Bros. Investments II, L.P.
  
6/1/2011
     21  
Purchase
     27.5103  
Baker Brothers Life Sciences, L.P.
  
6/1/2011
     34379  
Purchase
     27.5103  
14159, L.P.
  
6/1/2011
     821  
Purchase
     27.5103  
Baker Bros. Investments II, L.P.
  
6/7/2011
     27  
Purchase
     26.1685  
Baker Brothers Life Sciences, L.P.
  
6/7/2011
     43763  
Purchase
     26.1685  
14159, L.P.
  
6/7/2011
     1045  
Purchase
     26.1685  
Baker Bros. Investments II, L.P.
  
6/7/2011
     16  
Purchase
     16.1421  
Baker Brothers Life Sciences, L.P.
  
6/7/2011
     25435  
Purchase
     26.1421  
14159, L.P.
  
6/7/2011
     607  
Purchase
     26.1421  
Baker Bros. Investments II, L.P.
  
6/8/2011
     15  
Purchase
     26.15  
Baker Brothers Life Sciences, L.P.
  
6/8/2011
     24402  
Purchase
     26.15  
14159, L.P.
  
6/8/2011
     583  
Purchase
     26.15  
Baker Bros. Investments II, L.P.
  
6/8/2011
     5  
Purchase
     26.1134  
Baker Brothers Life Sciences, L.P.
  
6/8/2011
     8746  
Purchase
     26.1134  
14159, L.P.
  
6/8/2011
     209  
Purchase
     26.1134  
Baker Bros. Investments II, L.P.
  
6/8/2011
     7  
Purchase
     26.1  
Baker Brothers Life Sciences, L.P.
  
6/8/2011
     11415  
Purchase
     26.1  
14159, L.P.
  
6/8/2011
     273  
Purchase
     26.1  
Baker Bros. Investments II, L.P.
  
6/9/2011
     45  
Purchase
     26.25  
Baker Brothers Life Sciences, L.P.
  
6/9/2011
     82031  
Purchase
     26.25  
14159, L.P.
  
6/9/2011
     1524  
Purchase
     26.25  
Baker Bros. Investments II, L.P.
  
6/9/2011
     3  
Purchase
     26.2974  
Baker Brothers Life Sciences, L.P.
  
6/9/2011
     5996  
Purchase
     26.2974  
14159, L.P.
  
6/9/2011
     112  
Purchase
     26.2974  
Baker Bros. Investments II, L.P.
  
6/9/2011
     1  
Purchase
     26.35  
Baker Brothers Life Sciences, L.P.
  
6/9/2011
     1864  
Purchase
     26.35  
14159, L.P.
  
6/9/2011
     35  
Purchase
     26.35  

 
Page 5 of 8 Pages
 
 
Item 6.
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
 
Except as reported herein, neither of the Reporting Persons has any express contracts, arrangements or understandings with any other Reporting Person with respect to the securities of the Company.  Except as set forth in Item 7 below, none of the Reporting Persons has any contracts, arrangements, understandings or relationships with the Company.
 
Item 7.
Material to Be Filed as Exhibits.
 
Exhibit 1.
Agreement regarding the joint filing of this statement.
 
 
Page 6 of 8 Pages
 
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
June 9, 2011

 
By:
/s/ Julian C. Baker
   
Julian C. Baker
     
 
By:
/s/ Felix J. Baker
   
Felix J. Baker

 
Page 7 of 8 Pages